Shots:

• The approval will increase the production capacity of Ruconest and allows Pharming to release the therapy manufactured at the facility during the approval process for commercialization in the EU
• The news facility is expected to reduce the risk of short-term pressure on the supply of Ruconest in the EU market targeting the needs of patients with hereditary angioedema
• Ruconest is a recombinant human C1 esterase inhibitor- approved to treat HAE attacks in the US- EU- Israel and South Korea with the expected approval for the establishment of its new facility in the US in H1’20

Click here to­ read full press release/ article | Ref: Pharming  | Image: Solebury Trout Access